Trimedika Limited - Accounts to registrar (filleted) - small 18.2

Trimedika Limited - Accounts to registrar (filleted) - small 18.2


IRIS Accounts Production v22.1.4.3 NI636113 Board of Directors 1.1.21 31.12.21 31.12.21 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureNI6361132020-12-31NI6361132021-12-31NI6361132021-01-012021-12-31NI6361132019-12-31NI6361132020-01-012020-12-31NI6361132020-12-31NI636113ns16:NorthernIreland2021-01-012021-12-31NI636113ns15:PoundSterling2021-01-012021-12-31NI636113ns11:Director12021-01-012021-12-31NI636113ns11:PrivateLimitedCompanyLtd2021-01-012021-12-31NI636113ns11:SmallEntities2021-01-012021-12-31NI636113ns11:AuditExempt-NoAccountantsReport2021-01-012021-12-31NI636113ns11:SmallCompaniesRegimeForDirectorsReport2021-01-012021-12-31NI636113ns11:SmallCompaniesRegimeForAccounts2021-01-012021-12-31NI636113ns11:FullAccounts2021-01-012021-12-31NI63611312021-01-012021-12-31NI636113ns11:Director22021-01-012021-12-31NI636113ns11:Director32021-01-012021-12-31NI636113ns11:RegisteredOffice2021-01-012021-12-31NI636113ns6:CurrentFinancialInstruments2021-12-31NI636113ns6:CurrentFinancialInstruments2020-12-31NI636113ns6:ShareCapital2021-12-31NI636113ns6:ShareCapital2020-12-31NI636113ns6:SharePremium2021-12-31NI636113ns6:SharePremium2020-12-31NI636113ns6:RetainedEarningsAccumulatedLosses2021-12-31NI636113ns6:RetainedEarningsAccumulatedLosses2020-12-31NI636113ns6:IntangibleAssetsOtherThanGoodwill2021-01-012021-12-31NI636113ns6:PatentsTrademarksLicencesConcessionsSimilar2021-01-012021-12-31NI636113ns6:DevelopmentCostsCapitalisedDevelopmentExpenditure2021-01-012021-12-31NI636113ns6:PlantMachinery2021-01-012021-12-31NI636113ns6:PatentsTrademarksLicencesConcessionsSimilar2020-12-31NI636113ns6:DevelopmentCostsCapitalisedDevelopmentExpenditure2020-12-31NI636113ns6:PatentsTrademarksLicencesConcessionsSimilar2021-12-31NI636113ns6:DevelopmentCostsCapitalisedDevelopmentExpenditure2021-12-31NI636113ns6:PatentsTrademarksLicencesConcessionsSimilar2020-12-31NI636113ns6:DevelopmentCostsCapitalisedDevelopmentExpenditure2020-12-31NI636113ns6:FurnitureFittings2020-12-31NI636113ns6:ComputerEquipment2020-12-31NI636113ns6:FurnitureFittings2021-01-012021-12-31NI636113ns6:ComputerEquipment2021-01-012021-12-31NI636113ns6:FurnitureFittings2021-12-31NI636113ns6:ComputerEquipment2021-12-31NI636113ns6:FurnitureFittings2020-12-31NI636113ns6:ComputerEquipment2020-12-31NI636113ns6:WithinOneYearns6:CurrentFinancialInstruments2021-12-31NI636113ns6:WithinOneYearns6:CurrentFinancialInstruments2020-12-31
REGISTERED NUMBER: NI636113 (Northern Ireland)















UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2021

FOR

TRIMEDIKA LIMITED

TRIMEDIKA LIMITED (REGISTERED NUMBER: NI636113)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021










Page

Company Information 1

Balance Sheet 2 to 3

Notes to the Financial Statements 4 to 7


TRIMEDIKA LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2021







DIRECTORS: Ms J A Brien
Dr. R Molloy
P Molloy





REGISTERED OFFICE: E3 Building Springvale Campus
398 Springfeld Road
Belfast
Co. Antrim
BT12 7DU





REGISTERED NUMBER: NI636113 (Northern Ireland)





ACCOUNTANTS: Baker Tilly Mooney Moore
17 Clarendon Road
Clarendon Dock
Belfast
BT1 3BG

TRIMEDIKA LIMITED (REGISTERED NUMBER: NI636113)

BALANCE SHEET
31 DECEMBER 2021

31.12.21 31.12.20
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 232,320 191,788
Tangible assets 5 16,958 16,745
249,278 208,533

CURRENT ASSETS
Stocks 509,591 526,165
Debtors 6 1,124,676 1,053,590
Cash at bank 636,480 1,610,041
2,270,747 3,189,796
CREDITORS
Amounts falling due within one year 7 651,017 1,005,032
NET CURRENT ASSETS 1,619,730 2,184,764
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,869,008

2,393,297

CAPITAL AND RESERVES
Called up share capital 13 13
Share premium 290,388 290,388
Retained earnings 1,578,607 2,102,896
1,869,008 2,393,297

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2021 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

TRIMEDIKA LIMITED (REGISTERED NUMBER: NI636113)

BALANCE SHEET - continued
31 DECEMBER 2021


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 1 June 2022 and were signed on its behalf by:





P Molloy - Director


TRIMEDIKA LIMITED (REGISTERED NUMBER: NI636113)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021


1. STATUTORY INFORMATION

Trimedika Limited is a private company, limited by shares , registered in Northern Ireland. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of ten years.

Development costs are being amortised evenly over their estimated useful life of ten years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 33% on cost and 20% on reducing balance

Fixtures, Fittings and equipment - 20% reducing balance

Computer Equipment - 20% reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

TRIMEDIKA LIMITED (REGISTERED NUMBER: NI636113)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2021


2. ACCOUNTING POLICIES - continued

Financial instruments
All financial instruments of the company are considered to meet the definition of basic financial instruments.

- Short term debtors and creditors
Debtors and creditors with no stated interest rate and are receivable or payable on demand are recognised at transaction price, and subject to annual impairment reviews. Any losses arising on impairment are recognised in the profit and loss account.

- Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and in hand.

- Loans and borrowings
All loans and borrowings are initially recorded at the present value of cash payable to the lender in settlement of the liability discounted at the market interest rate. Subsequently loans and borrowings are stated at amortised cost using the effective interest rate method. The computation of amortised cost includes any issue costs, transaction costs and fees, and any discount or premium on settlement, and the effect of this is to amortise these amounts over the expected borrowing period. Loans with no stated interest rate and repayable within one period or on demand are not amortised. Loans and borrowings are classified as current liabilities unless the borrower has an unconditional right to defer settlement of the liability for at least 12 months after the financial period end date.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 17 (2020 - 9 ) .

TRIMEDIKA LIMITED (REGISTERED NUMBER: NI636113)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2021


4. INTANGIBLE FIXED ASSETS
Patents
and Development
licences costs Totals
£    £    £   
COST
At 1 January 2021 51,548 147,028 198,576
Additions 12,369 59,073 71,442
Disposals (2,140 ) - (2,140 )
At 31 December 2021 61,777 206,101 267,878
AMORTISATION
At 1 January 2021 1,678 5,110 6,788
Amortisation for year 11,220 18,064 29,284
Eliminated on disposal (514 ) - (514 )
At 31 December 2021 12,384 23,174 35,558
NET BOOK VALUE
At 31 December 2021 49,393 182,927 232,320
At 31 December 2020 49,870 141,918 191,788

5. TANGIBLE FIXED ASSETS
Fixtures,
fittings Computer
& equipment equipment Totals
£    £    £   
COST
At 1 January 2021 7,240 11,501 18,741
Additions - 4,007 4,007
Disposals - (72 ) (72 )
At 31 December 2021 7,240 15,436 22,676
DEPRECIATION
At 1 January 2021 668 1,328 1,996
Charge for year 1,314 2,425 3,739
Eliminated on disposal - (17 ) (17 )
At 31 December 2021 1,982 3,736 5,718
NET BOOK VALUE
At 31 December 2021 5,258 11,700 16,958
At 31 December 2020 6,572 10,173 16,745

TRIMEDIKA LIMITED (REGISTERED NUMBER: NI636113)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2021


6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.21 31.12.20
£    £   
Trade debtors 60,545 (605 )
Other debtors 1,064,131 1,054,195
1,124,676 1,053,590

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.21 31.12.20
£    £   
Trade creditors 93,141 171,955
Taxation and social security 492,447 554,599
Other creditors 65,429 278,478
651,017 1,005,032

8. CONTINGENT LIABILITIES

A contingent liability may exist in respect of a repayment of grant income should the conditions under which a grant was awarded to the company not be met. Due to the nature of these contingencies, it is not currently possible to estimate the likelihood of this occurring, nor quantify the financial effect or provide an indication of timing as to the potential liability that may arise.